TCIM
ACRS icon

TIAA CREF Investment Management’s Aclaris Therapeutics ACRS Stock Holding History

TIAA CREF Investment Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$467K Sell
77,958
-45,983
-37% -$305K ﹤0.01% 2625
2018
Q4 		$916K Sell
123,941
-58,578
-32% -$604K ﹤0.01% 2318
2018
Q3 		$2.65M Sell
182,519
-22,512
-11% -$386K ﹤0.01% 1971
2018
Q2 		$4.09M Buy
205,031
+2,213
+1% +$40.9K ﹤0.01% 1746
2018
Q1 		$3.55M Hold
202,818
– – ﹤0.01% 1780
2017
Q4 		$5M Sell
202,818
-27,330
-12% -$666K ﹤0.01% 1594
2017
Q3 		$5.94M Buy
230,148
+15,207
+7% +$408K ﹤0.01% 1513
2017
Q2 		$5.83M Buy
214,941
+36,667
+21% +$997K ﹤0.01% 1498
2017
Q1 		$5.32M Sell
178,274
-1,108
-0.6% -$31.9K ﹤0.01% 1559
2016
Q4 		$4.87M Buy
179,382
+150,942
+531% +$3.85M ﹤0.01% 1626
2016
Q3 		$728 Hold
28,440
– – ﹤0.01% 2703
2016
Q2 		$525K Buy
28,440
+15,487
+120% +$307K ﹤0.01% 2833
2016
Q1 		$245K Hold
12,953
– – ﹤0.01% 2952
2015
Q4 		$349K Buy
+12,953
New +$252K ﹤0.01% 2989

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

TIAA CREF Investment Management's ACRS Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Aclaris Therapeutics (ACRS) stake by 37% in Q1 2019, selling an estimated $305K and leaving 77,958 shares worth $467K. The position accounts for ﹤0.01% of the portfolio, ranked #2625.

TIAA CREF Investment Management first reported a position in ACRS in Q4 2015 and has held it in 14 quarters since. The position peaked at $5.94M in Q3 2017. 95 funds tracked by Wall St. Rank hold ACRS as of Q1 2019.

  • TIAA CREF Investment Management held 77,958 shares of Aclaris Therapeutics worth $467K as of Q1 2019.
  • TIAA CREF Investment Management sold 45,983 Aclaris Therapeutics shares in Q1 2019, an estimated $305K.
  • Aclaris Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2625 holding.
  • TIAA CREF Investment Management first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 14 quarters since.
  • TIAA CREF Investment Management's Aclaris Therapeutics position peaked at $5.94M in Q3 2017.
  • 95 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.